Key Insights

Highlights

Success Rate

96% trial completion (above average)

Published Results

21 trials with published results (30%)

Research Maturity

55 completed trials (80% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

2.9%

2 terminated out of 69 trials

Success Rate

96.5%

+10.0% vs benchmark

Late-Stage Pipeline

42%

29 trials in Phase 3/4

Results Transparency

38%

21 of 55 completed with results

Key Signals

21 with results96% success

Data Visualizations

Phase Distribution

59Total
Not Applicable (16)
Early P 1 (1)
P 1 (9)
P 2 (4)
P 3 (16)
P 4 (13)

Trial Status

Completed55
Unknown6
Recruiting5
Terminated2
Active Not Recruiting1

Trial Success Rate

96.5%

Benchmark: 86.5%

Based on 55 completed trials

Clinical Trials (69)

Showing 20 of 20 trials
NCT07379645Not ApplicableRecruitingPrimary

A Clinical Trial of PepZinGI® for Acute Heartburn Relief and Sleep Outcomes

NCT01696734Phase 3Recruiting

Domperidone in Treating Patients With Gastrointestinal Disorders

NCT05976165Not ApplicableRecruiting

A Study of Breath Testing for Small Intestinal Bacterial Overgrowth

NCT06075082Not ApplicableCompleted

The Effect of the LEFT Smartwatch App as Sleep Positional Therapy for Nocturnal Gastroesophageal Reflux Symptoms.

NCT06660342Recruiting

A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring

NCT06952855Completed

Observationa Study is a Prospective and Multi-institutional Observational Study.

NCT06391177Phase 1Completed

A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily

NCT06094062Not ApplicableCompletedPrimary

Smartphone App-assisted PPI

NCT05629143Phase 4Active Not RecruitingPrimary

Primary carE PPi dEprescRibing Trial

NCT04560595Not ApplicableCompleted

Remote Guided Caffeine Reduction

NCT06552624Not ApplicableCompletedPrimary

Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg Chewable Tablets and Riopan 800 mg Chewable Tablets in Healthy Volunteers

NCT06098742Not ApplicableRecruitingPrimary

Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg/10 ml Oral Suspension and Riopan 800 mg Chewable Tablets in Healthy Volunteers

NCT06293326Phase 1CompletedPrimary

A First-in-Human Study to Learn How Well a Bi-Layer Calcium Carbonate Antacid Tablet Works Compared to a Standard, Non-Layered Calcium Carbonate Tablet in Healthy Male Participants

NCT05195528Phase 3Completed

A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)

NCT05247333Not ApplicableCompleted

Implementation of a Minor Ailment Service in Community Pharmacy Practice

NCT05363618Not ApplicableCompletedPrimary

Tolerability Study of Panosyl-Isomaltooligosaccharides (PIMO) and a Placebo in Subjects With Heartburn

NCT05901740UnknownPrimary

Prevalence of Fuctional Heartburn in Patients With IBS .

NCT04799158Phase 2Completed

A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease

NCT02623816Phase 4CompletedPrimary

Symptom Control Satisfaction With Proton Pump Inhibitor Regimen

NCT04252144Not ApplicableUnknown

Study of Dietary Patterns and Food Diversity in Russian GERD Patients

Scroll to load more

Research Network

Activity Timeline